P1.01-052 Patient-Reported Outcomes (Pros) in Oak: A Phase Iii Study of Atezolizumab vs Docetaxel in Non-Small-Cell Lung Cancer (Nsclc)
Bordoni, R.; Ciardiello, F.; Von Pawel, J.; Cortinovis, D.; He, P.; Karagiannis, T.; Ballinger, M.; Sandler, A.; Yu, W.; Felizzi, F.; Rittmeyer, A.
Journal of Thoracic Oncology 12(11): S1914-S1915
2017
ISSN/ISBN: 1556-0864
DOI: 10.1016/j.jtho.2017.09.706
Accession: 067001676
PDF emailed within 0-6 h: $19.90
Related References
Wu, Y.; Chang, J.; Zhang, L.; Tu, H.; Wu, L.; Feng, J.; Lu, S.; Zhou, C.; Wang, J.; Mok, T.; Taylor, F.; Mossman, B.; Penrod, J.; Lawrance, R.; Blum, S. 2018: Oa10 Check Mate 078: Patient-Reported Outcomes (Pros) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (Nsclc) Journal of Thoracic Oncology 13(12): S1047-S1048Bordoni, R.; Ciardiello, F.; von Pawel, J.; Cortinovis, D.; Karagiannis, T.; Ballinger, M.; Sandler, A.; Yu, W.; He, P.; Matheny, C.; Felizzi, F.; Rittmeyer, A. 2018: Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer Clinical Lung Cancer 19(5): 441-449.E4
Perol, M.; Peters, S.; Pavlakis, N.; Levchenko, E.; Platania, M.; Oliveira, J.; Novello, S.; Karagiannis, T.; Zeaiter, A.; Dziadziuszko, R. 2018: 138Pd_Pr Patient-reported outcomes (Pros) in Alex: A phase Iii study of alectinib (Alec) vs crizotinib (Criz) in non-small-cell lung cancer (Nsclc) Journal of Thoracic Oncology 13(4): S80-S81
Jahanzeb, M.; Lin, H.M.; Pan, X.; Yin, Y.; Hou, P.; Nordstrom, B.L.; Desai, A.; Socinski, M.A. 2018: Real-world progression-free survival of patients on anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) for ALK+ non-small cell lung cancer (NSCLC) Annals of Oncology: Official Journal of the European Society for Medical Oncology 29 Suppl. 8: Viii504
Taguchi, S.; Nakagawa, T.; Fukuhara, H. 2020: Inconsistencies in currently used definitions of sarcopenia in oncology Annals of Oncology: Official Journal of the European Society for Medical Oncology 31(2): 318-319
Kuruvilla, P.G.; Krieger, H.; Zibdawi, L.; Meharchand, J.; Solow, H.; Leighl, N.; Chin, C.; Stewart, J.A.; Hollen, P.J.; Gralla, R.J. 2016: Assessing quality of life (QL) and patient reported outcomes (PROs) in clinical trials and clinical practice: A study using a hand-held computerized form of the validated LCSS instrument in patients with non-small cell lung cancer (NSCLC) Journal of Clinical Oncology 23(16_Suppl): 8067-8067
Rubio, J.C.; Estevez, S.V.; Quintela, M.L.; Balea, B.C.; Ventura, C.G.; Tunas, L.V.; Manrique, K.A.; Gomez, J.L.F.; Gancedo, M.A.; Silva, M.C. 2007: Induction docetaxel and cisplatin followed by bi-weekly docetaxel with concurrent thoracic radiotherapy for stage III non-small cell lung cancer (NSCLC). A phase II study conducted by the Galician Lung Cancer Group (GLCG) EJC Suppls 5(4): 388-389
Casal Rubio, J.; Vazquez Estevez, S.; Lazaro Quintela, M.; Campos Balea, B.; Grande Ventura, C.; Vazquez Tuñas, L.; Areses Manrique, K.; Firvida Gomez, J.L.; Amenedo Gancedo, M.; Silva, M.C. 2007: Poster Induction docetaxel and cisplatin followed by bi-weekly docetaxel with concurrent thoracic radiotherapy for stage Iii non-small cell lung cancer (Nsclc). A phase Ii study conducted by the Galician Lung Cancer Group (Glcg) European Journal of Cancer Suppls 5(4): 388-389
Chen, Y.; Pandya, K.J.; Smudzin, T.; Qazi, R.; Smith, B.D.; Hyrien, O.; Johnstone, D.W.; Watson, T.; Feins, R.H. 2016: Phase II study of induction docetaxel/cisplatin with rhG-CSF followed by concurrent pulsed docetaxel chemoradiation for stage III non-small cell lung cancer (NSCLC) Journal of Clinical Oncology 24(18_Suppl): 17034-17034
Huber, R M.; Flentje, M; Willner, J.; Borgmeier, A; Schmidt, M; Manegold, C.; Debus, J.; Pöllinger, B 2003: P-591 Concurrent chemoradiotherapy (CTRT) with docetaxel and cisplatin followed by docetaxel consolidation therapy (DCT) in patients with inoperable stage IIIA/B non-small cell lung cancer (NSCLC): a phase I study Lung Cancer 41: S240-S241
Herbst, R.S.; Sun, Y.; Korfee, S.; Germonpré, P.; Saijo, N.; Zhou, C.; Wang, J.; Langmuir, P.; Kennedy, S.J.; Johnson, B.E. 2016: Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC) Journal of Clinical Oncology 27(18_Suppl): Cra 8003-Cra 8003
Giaccone, G.; Camidge, D.R.; Liu, S.V.; Powderly, J.; Hodi, F.S.; Gettinger, S.N.; Heist, R.S.; Liu, B.; Wallin, J.; Funke, R.; Waterkamp, D.; Ready, N.E. 2015: Safety, activity and biomarkers of atezolizumab (Mpdl3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (Nsclc): A Phase Ib study European Journal of Cancer 51: S107-S108
L.C.er, H.; Gimenez, C.; Fournel, P.; Chouaid, C.; Robinet, G.; Jullian, H.; Vergnenegre, A.; Bayle, S.; Barlesi, F.; Barriere, J.R. 2016: A multicenter phase II study of docetaxel (D) or docetaxel/gemcitabine (G) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts).(GFPC 0202) Journal of Clinical Oncology 23(16_Suppl): 7150-7150
Ouwens, M.; Darilay, A.; Zhang, Y.; Mukhopadhyay, P.; Mann, H.; Ryan, J.; Dennis, P.A. 2019: Impact of subsequent post-discontinuation immunotherapy on overall survival in patients with unresectable, stage III NSCLC from PACIFIC Annals of Oncology: Official Journal of the European Society for Medical Oncology 30 Suppl. 2: Ii31
Rittmeyer, A.; Barlesi, F.; Waterkamp, D.; Park, K.; Ciardiello, F.; von Pawel, J.; Gadgeel, S.M.; Hida, T.; Kowalski, D.M.; Dols, M.C.; Cortinovis, D.L.; Leach, J.; Polikoff, J.; Barrios, C.; Kabbinavar, F.; Frontera, O.A.én.; De Marinis, F.; Turna, H.; Lee, J.-S.; Ballinger, M.; Kowanetz, M.; He, P.; Chen, D.S.; Sandler, A.; Gandara, D.R. 2017: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Lancet 389(10066): 255-265